NovoCure (NVCR) Stock Forecast & Price Target

→ Did You Get Your Free Bitcoin Yet? (From Crypto Swap Profits) (Ad)

$12.72

-0.85 (-6.26%)

(As of 04/15/2024 ET)

NovoCure Consensus Analyst Rating and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Moderate Buy
Based on 9 Analyst Ratings

Analysts' Consensus Price Target

$31.13
144.69% Upside

High Forecast	$51.00
Average Forecast	$31.13
Low Forecast	$15.00

Type	Current Forecast 4/17/23 to 4/16/24	1 Month Ago 3/18/23 to 3/17/24	3 Months Ago 1/17/23 to 1/17/24	1 Year Ago 4/17/22 to 4/17/23
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Hold
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	5 Buy rating(s)	6 Buy rating(s)	5 Buy rating(s)	2 Buy rating(s)
Hold	4 Hold rating(s)	2 Hold rating(s)	2 Hold rating(s)	2 Hold rating(s)
Sell	0 Sell rating(s)	1 Sell rating(s)	1 Sell rating(s)	2 Sell rating(s)
Consensus Price Target	$31.13	$38.00	$41.71	$87.33
Predicted Upside	144.69% Upside	42.15% Upside	43.56% Upside	4.94% Upside

Get NovoCure Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for NVCR and its competitors with MarketBeat's FREE daily newsletter.

Ad Crypto Swap Profits

Did You Get Your Free Bitcoin Yet?

And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.

>> Register right here

NVCR Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

NVCR Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

NovoCure Stock vs. The Competition

Type	NovoCure	Medical Companies	S&P 500
Consensus Rating Score	2.56	2.68	2.49
Consensus Rating	Moderate Buy	Moderate Buy	Hold
Predicted Upside	144.69% Upside	882.68% Upside	11.19% Upside
News Sentiment Rating	Positive News	Positive News	Positive News

Recent Analyst Ratings and Stock Forecasts

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
4/10/2024	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Overweight ➝ Overweight	$25.00 ➝ $28.00	+88.17%
4/3/2024	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$49.00 ➝ $42.00	+194.53%
3/27/2024	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Neutral	$21.00	+43.44%
3/27/2024	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral ➝ Neutral	$22.00 ➝ $24.00	+57.38%
3/19/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral ➝ Neutral	$15.00 ➝ $17.00	+25.18%
2/23/2024	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	In-Line ➝ In-Line	$14.00 ➝ $15.00	-1.57%
8/4/2023	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	J. Chang Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
8/4/2023	SVB Leerink Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$51.00	+75.26%
8/4/2023	SVB Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$51.00	+75.26%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 09:04 AM ET.

NVCR Price Target - Frequently Asked Questions

What is NovoCure's consensus rating and price target?: According to the issued ratings of 9 analysts in the last year, the consensus rating for NovoCure stock is Moderate Buy based on the current 4 hold ratings and 5 buy ratings for NVCR. The average twelve-month price prediction for NovoCure is $31.13 with a high price target of $51.00 and a low price target of $15.00. Learn more on NVCR's analyst rating history.
Do Wall Street analysts like NovoCure more than its competitors?: Analysts like NovoCure less than other Medical companies. The consensus rating score for NovoCure is 2.56 while the average consensus rating score for medical companies is 2.68. Learn more on how NVCR compares to other companies.
Does NovoCure's stock price have much upside?: According to analysts, NovoCure's stock has a predicted upside of 70.49% based on their 12-month stock forecasts.

What analysts cover NovoCure?: NovoCure has been rated by Evercore ISI, HC Wainwright, JPMorgan Chase & Co., Piper Sandler, Wedbush, and Wells Fargo & Company in the past 90 days.

Stock Ratings Reports and Tools

Related Companies:

Today's Ratings:

Top Rated Stocks:

More Ratings Tools:

This page (NASDAQ:NVCR) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

NovoCure (NVCR) Stock Forecast & Price Target

NovoCure Consensus Analyst Rating and Stock Price Forecast (2024)

Analysts' Consensus Rating

Analysts' Consensus Price Target

NVCR Analyst Ratings By Month

NVCR Price Targets by Month

NovoCure Stock vs. The Competition

Recent Analyst Ratings and Stock Forecasts

NVCR Price Target - Frequently Asked Questions

Stock Ratings Reports and Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info